Click a link below to view the mailing archive as if it had been sent to you.
| 2024-06-28 12:15 | | Alumis cuts IPO size, but nets $250M for immune drug work and more... |
| 2024-06-28 00:15 | | Silence breaks down phase 1 data on blood disorder prospect, sharing glimpse at pitch for competitive niche and more... |
| 2024-06-27 12:15 | | Supreme Court rejects controversial Purdue Pharma bankruptcy deal and more... |
| 2024-06-26 12:15 | | After full approval, Sarepta lays out its next moves and more... |
| 2024-06-26 00:15 | | Sanofi Seeks Initial Offers for Its $20 Billion Consumer Arm and more... |
| 2024-06-25 12:15 | | Finland to start bird flu vaccinations for humans, in world first and more... |
| 2024-06-25 00:15 | | Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass and more... |
| 2024-06-24 12:15 | | 5 FDA Decisions to Watch in the Second Half of 2024 and more... |
| 2024-06-21 12:15 | | Chronic kidney disease market estimated to grow at 19.6%, driven by pipeline agents aimed at unmet needs and more... |
| 2024-06-21 00:15 | | Sarepta Duchenne gene therapy wins broader use from FDA and more... |
| 2024-06-20 12:15 | | Biopharma dealmaking continues to rise, but M&A values hold steady: PwC and more... |
| 2024-06-19 00:15 | | FTC backs rule change that could expose anticompetitive drug patent deals and more... |
| 2024-06-18 12:15 | | AstraZeneca’s Truqap flops in phase III triple-negative breast cancer trial and more... |
| 2024-06-18 00:15 | | Merck gets shot in the arm with FDA approval for first pneumococcal vaccine designed for adults and more... |
| 2024-06-17 12:15 | | FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness' and more... |
| 2024-06-17 00:15 | | Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy and more... |
| 2024-06-14 12:15 | | GLP-1 global obesity market to reach $111B by 2033, despite headwinds: GlobalData and more... |
| 2024-06-14 00:15 | | Pfizer expects 8 blockbuster cancer drugs to come from each of 4 focus areas: exec and more... |
| 2024-06-13 12:15 | | Coherus, Junshi’s PD-1 blocker Loqtorzi aces phase III liver cancer trial and more... |
| 2024-06-13 00:15 | | Pfizer gene therapy for Duchenne fails to meet goals of key trial and more... |
| 2024-06-12 12:15 | | The 6 largest biopharma layoffs of 2024 so far and more... |
| 2024-06-12 00:15 | | Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’ and more... |
| 2024-06-11 12:15 | | After M&A stretch, Pfizer CEO says company needs 'breathing period' from large deals and more... |
| 2024-06-11 00:15 | | Lilly Alzheimer’s drug gets unanimous backing of FDA panel and more... |
| 2024-06-10 12:15 | | Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study and more... |
| 2024-06-10 00:15 | | Would BIO support a biosecurity bill targeting drug developers? Hear CEO John Crowley’s response and more... |
| 2024-06-09 00:15 | | GSK exec lauds 'great start' to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 |
| 2024-06-07 12:15 | | AbbVie's tight grip on Humira market raises concerns about biosimilars and more... |
| 2024-06-07 00:15 | | After AbbVie's ImmunoGen buy, Elahere posts midstage trial win in ovarian cancer subtype and more... |
| 2024-06-06 12:15 | | GSK, after 11-month romance, buys oligonucleotide partner Elsie for up to $50M and more... |
| 2024-06-06 00:15 | | Bristol Myers puts more than 860 jobs on chopping block in NJ as $1.5B savings campaign rolls ahead and more... |
| 2024-06-05 12:15 | | Companies to watch for potential M&As in 2024 and more... |
| 2024-06-05 00:15 | | FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns and more... |
| 2024-06-04 12:15 | | ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer and more... |
| 2024-06-04 00:15 | | Agios Blood Disorder Drug Scores Another Phase III Win and more... |
| 2024-06-03 12:15 | | Edwards to sell critical care products unit to Becton Dickinson for $4.2 bln and more... |
| 2024-06-03 00:15 | | ASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclear and more... |
